ETF와이어ETF·펀드·패시브 투자, 매일 5분으로
etf1 min

KOSPI Slides Over 3% After 7,900 Break as Foreigners Sell 3 Trillion Won

Published: · Source: mk.co.kr

KOSPI Slides Over 3% After 7,900 Break as Foreigners Sell 3 Trillion Won
TL;DR: The KOSPI briefly topped 7,900 for the first time, nearing the 8,000 mark, but reversed sharply as foreign investors sold about 3 trillion won and profit-taking hit the market.
Advertisement
11개 언어 자동 번역

The KOSPI briefly broke above the 7,900 level for the first time during trading, moving close to the symbolic 8,000 mark, but it turned sharply lower as foreign selling intensified. The index fell by more than 3% as profit-taking followed its recent rapid rise. Foreign investors placed roughly 3 trillion won in sell orders, adding to market volatility. Although the intraday record lifted investor sentiment at first, heavy selling quickly reversed the upward momentum. With pressure from the short-term rally now evident, future supply and demand flows are set to remain a key factor for the index. Source: mk.co.kr.

Advertisement
Get notifications

Partner picks

Relevant partner links for this story

A lightweight commerce block designed to add monetization without breaking reading flow.

This module may include affiliate links that earn a commission from qualifying purchases. ETF와이어

Sponsored
Get notifications
Subscribe to our daily digest
Advertisement
매일 5분 안에 핵심 뉴스

Related stories

KOSPI Jumps 81% Toward 8,000, While KOSDAQ’s 28% Rise Tests 3,000
etf1 min

KOSPI Jumps 81% Toward 8,000, While KOSDAQ’s 28% Rise Tests 3,000

As South Korean stocks keep setting record highs, the KOSPI has climbed 81% this year, fueling hopes for 8,000, while the KOSDAQ’s 28% gain leaves its 3,000 test in focus.

mk.co.kr
Hyosung Goodsprings to Debut High-Efficiency Pump Solution at HVAC KOREA 2026
etf1 min

Hyosung Goodsprings to Debut High-Efficiency Pump Solution at HVAC KOREA 2026

Hyosung Goodsprings will unveil a high-efficiency pump solution that cuts power use by 3.2% at HVAC KOREA 2026 from May 13 to 15, alongside solutions for data centers and building facilities.

mk.co.kr
Aprogen Osteoarthritis Drug AP209 Targets First Patient Dosing in Early August
etf1 min

Aprogen Osteoarthritis Drug AP209 Targets First Patient Dosing in Early August

Aprogen said it filed a clinical trial application for its osteoarthritis drug AP209 with South Korea’s Ministry of Food and Drug Safety in March and expects approval in late May or early June.

mk.co.kr